References
- 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Infect Dis Obstet Gynecol 2002;10:3–64.
- Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322: 161–5
- Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178: 1126–32
- Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22–9
- 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1–19.
- Coates RA, Farewell VT, Raboud J, Read SE, Klein M, MacFadden DK, et al. Using serial observations to identify predictors of progression to AIDS in the Toronto Sexual Contact Study. J Clin Epidemiol 1992; 45: 245–53
- Glick M, Muzyka BC, Lurie D, Salkin LM. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994; 77: 344–9
- Katz MH, Greenspan D, Westenhouse J, Hessol NA, Buchbinder SP, Lifson AR, et al. Progression to AIDS in HIV-infected homosexual and bisexual men with hairy leukoplakia and oral candidiasis. AIDS 1992; 6: 95–100
- Patton LL. Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 182–8
- Hilton JF. Functions of oral candidiasis episodes that are highly prognostic for AIDS. Stat Med 2000; 19: 989–1004
- Fernandez-Feijoo J, Diz-Dios P, Otero-Cepeda XL, Limeres-Posse J, de lF-A, Ocampo-Hermida A. Predictive value of oral candidiasis as a marker of progression to AIDS Med Oral Patol Oral Cir Bucal 2005;10:36–40.
- Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, et al. Factors associated with development of opportunistic infections in HIV-1 infected adults with high CD4 cell counts: a EuroSIDA study. J Infect Dis 2006; 194: 633–41
- The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 2006;355:2283–96.
- Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. AIDS 1999; 13: 943–50
- Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, et al. Short-term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score. AIDS 2007; 21: 1867–75
- Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3: 533–40
- Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, et al. Safe interruption of maintenance therapy against previous infection with 4 common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239–50
- Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371: 1443–51